ABN/ARSN

15 088 417 403

Rule 3.8A

## Appendix 3E

## Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Name of entity

Sigma Pharmaceuticals Limited

C	ormation about buy-back		
	Type of buy-back	On-market buy-back	
	Date Appendix 3C was given to ASX0	13 September 2012	
	al of all shares/units bought	hack or in relation to	a which accent
	e been received, before, and	· · · · · · · · · · · · · · · · · · ·	Previous day
	9	on, previous day	_
	9	on, previous day	_

		Before p	revious	s day	Previous day
5	If buy-back is an on-market buy-back	Highest \$0.8525	price	paid:	Highest price paid: \$0.7500
					Lowest price paid: \$0.7400
		\$0.6250	price	paid:	Highest price allowed under rule 7.33: \$0.7781

## How many shares/units may still be bought back?

6	If the company/trust has disclosed an intention to buy back a maximum number of shares/units — the remaining number of shares/units to be bought back	59,502,376

## **Compliance statement**

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here: Date: 24 July 2013

(Director/Company secretary)

Print name: SUE MORGAN